The United States (US) Congress has designated January to be Cervical Health Awareness Month, and for good reason; at one time, cervical cancer was the leading cause of cancer death for women in the US. The incidence of cervical cancer is not restricted to the US or to developed nations, however. Cervical cancer is the fourth most common cancer in women worldwide, and represents approximately 8% of all female cancers.
Bethyl has applied B-cell sorting and recombinant DNA technology to our unparalleled on-site manufacturing process to deliver high quality recombinant rabbit monoclonal antibodies (RmAbs). Designed with a 100% guarantee to work in validated applications to ensure that you spend less time re-doing experiments and more time researching.
Immune checkpoint blockade has emerged over the past decade as a useful therapeutic tool against many types of tumors. The most commonly known checkpoint that can be targeted therapeutically is the PD-1/PD-L1 pathway. Bethyl's new PD-L1 recombinant rabbit monoclonal antibody was compared against the leading competitor's antibody and proved to be 8 times more sensitive.
Trial sizes are ideal for comparisons between suppliers or various application testings and cost effective at $99 US. Over 6,000 trial-sized antibodies are available to more than 3,300 protein targets, and new releases are continuing to be added every month.
Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.